Dear attending physicians:

Please remember that med students & residents are essentially changing jobs every 4 weeks, while you've been in your field for years.

Today, #OncLiveOnAir partners with Two Onc Docs to bring you insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting. TwoOncDocs Samantha Armstrong Karine Tawagi MD ASCO #ASCO24 #Oncology onclive.com/view/asco-2024…

Part 2 melanoma with the expert Dr. Mike Atkins this week discussing:

The Aha moment when he saw IO changing the landscape 🌟
When to use LAG3 combo
DREAMseq IO vs BRAF for which he was 1st author 🌟
Oligometastatic dx
Uveal / mucosal melanoma
Career tips

#meded

🗨️Looking for expert insights on the practice-changing #LAURA study?

🌟Don't miss this video, which features TwoOncDocs interviewing Suresh S. Ramalingam, MD, FASCO on his plenary presentation about the phase 3 trial during #ASCO24 !

📺Watch now: buff.ly/4c9PezU

#NSCLC #LCSM #ASCOLung

Texting with a non-medical friend about #ASCO24 be like:

Very grateful for the mentorship and sponsorship I have experienced in ECOG-ACRIN Cancer Research Group thanks to Angie DeMichele, MD, MSCE, FASCO Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Lynne I Wagner PhD , providing me the opportunity to disseminate EAZ171 today at #ASCO24

📸: Yara Abdou

Nice to wrap up #ASCO24 seeing colleagues and collaborators Ronak H. Mistry, DO Karine Tawagi MD Vivek Patel, MD Catherine Fahey in person. Congrats again to Ronak H. Mistry, DO on the oral and poster presentations highlighting #MedEd for Hem-Onc Fellows Network, looking forward to final data and manuscript!

⁉️Split response during the #ASCO24 session today!

A question to my #sarcoma colleagues:
Young patient with metastatic uLMS, what is first-line chemotherapy?

#CercekPlot Andrea Cercek achieved 42 out of 42 COMPLETE clinical responses in MMRd - #rectalcancer - 100%!! #ASCO24 ASCO Memorial Sloan Kettering Cancer Center

Discussing the practice changing #LAURA trial for stage 3 unresectable NSCLC for pts w/ EGFRm with the expert himself Suresh S. Ramalingam, MD, FASCO 🌟 including:

❓why placebo control
❓expected OS
❓why indefinite tx
❓role for other driver mutations

#ASCO24

Advanced penile cancer #HERCULES trial

➡️ cis or carbo + 5FU + pembro x6 cycles then maintenance pembro for responders
🌀59.5% black/AA pts
🌟met primary endpoint of ORR 39.4% - 3% CR, 36.4% PR
➡️ HPV16 & TMB potential predictive biomarkers

#ASCO24 - post by Karine Tawagi MD

Selfie lattes in the exhibit hall ☕️

Next up Rapid Oral Prostate/Testicular/Penile CA in Hall B1

Karine Tawagi MD Samantha Armstrong TwoOncDocs ASCO #ASCO24

Here is Karine Tawagi MD taking over updates the next few hours

Be sure to take a wellness break at Lakeside Lounge outside with this beautiful weather ☀️

w/ my partner in crime Samantha Armstrong TwoOncDocs ASCO #ASCO24

👏🏼🌟 The Fellow On Call Ronak H. Mistry, DO presenting on resources trainees are using for studying and clinical decision making! Honored to collaborate on this study 🤝 #ASCO24 #MedEd

Next up @danielpetrylak presenting data on monotherapy EV & impact of dose exposure

➡️ this 🏊 plot shows ongoing responses despite interruptions & reductions of EV to 1mg/kg or 0.75mg/kg

🌟 median onset to neuropathy was 4.7mo, rash 0.6mo, hyperglycemia 0.6mo

#ASCO24

Oral Bladder/RCC now with Shilpa Gupta presenting patient-reported outcomes from #EV302

🌟 improved PFS and OS w/ EV/P vs chemo w/o detriment to QoL or pain/functioning
🌀 would like to see data on impact of neuropathy as this was not captured w/ EORTC Qs

#ASCO24

So proud to see theMednet highlighted by Samuel Kareff, MD, MPH among the growing list of digital education platforms available for hem/onc fellows (and more) at the ASCO OncMedEdCoP scholarship session this morning!! 🙌🏼 #ASCO24 #ASCOMedEdCoP

Check out all these exciting med ed presentations today!! 🌟ASCO

The Fellow On Call 🤝 TwoOncDocs

Thank you Lynn Schuchter and ASCO for having us at the President’s Reception!

#HemeOnc #OncMedEd #MedEdFam